Quest Diagnostics Incorporated

What they do

Quest Diagnostics provides clinical laboratory testing and diagnostic insights to physicians, hospitals, patients, and consumers through its Diagnostic Information Services (DIS) segment, which makes up over 95% of consolidated net revenues. The company also operates a Diagnostic Solutions (DS) group offering risk assessment services for insurers and healthcare IT solutions. Its services are accessed via a network of labs, patient service centers, physician office phlebotomists, and digital channels like QuestHealth.com.

Revenue drivers

• Diagnostic Information Services (DIS) — Core lab testing business, generating over 95% of revenue; grew 10.3% in Q2 2026 to $2.98 billion, driven by 13.1% requisition volume growth (13.0% organic).
• Advanced Diagnostics — High-growth specialized testing area including AD-Detect Alzheimer's blood tests, cardiometabolic/endocrine tests, and liver fibrosis testing; grew double-digits in Q2 2026.
• Consumer-initiated testing (QuestHealth.com) — Self-directed testing platform with physician oversight; reported robust revenue growth in Q2 2026.
• Diagnostic Solutions (DS) — Risk assessment services for insurers and healthcare IT solutions; contributed $65 million in Q2 2026, up from $62 million year-over-year.

Recent performance

In Q2 2026, Quest Diagnostics reported net revenues of $3.04 billion, up 10.2% from $2.76 billion in Q2 2025, with 10.0% organic growth. Reported diluted EPS was $2.84, up 15.0% year-over-year; adjusted diluted EPS rose 19.1% to $3.12. Operating income was $459 million (15.1% of revenues), and net cash from operations was $597 million. For the first half of 2026, revenues totaled $5.94 billion, up 9.7%, and reported diluted EPS was $5.08.

Strategy

Quest Diagnostics focuses on growth through an industry-leading test menu, collaborations with healthcare providers, leveraging its data assets, and improving efficiency via automation and AI. Recent initiatives include the Corewell Health joint venture in Michigan (51% owned, consolidated) to expand lab testing, the Invigorate multi-year program to drive savings and productivity, and the launch of IntelliDraw to improve specimen collection. The company also emphasizes consumer and wellness partnerships, and advanced diagnostics innovation, including the NYS-approved Haystack MRD test.

Risks

• Volume concentration risk — Annual revenue growth relies on requisition volume; a slowdown in organic volume growth (13.0% in Q2 2026 vs. 2.1% in Q2 2025) could pressure results.
• Pricing pressure — Revenue per requisition declined 2.8% in Q2 2026, reflecting fee schedule changes and payer mix shifts, which could offset volume gains.
• Integration and execution risk — The Corewell Health JV and other acquisitions require successful integration and operational performance; delays or cost overruns could impact financials.
• Debt and interest rate risk — Long-term debt was $5.63 billion as of June 30, 2026; higher interest rates or refinancing costs could increase expense and reduce profitability.

Outlook

Management raised full-year 2026 guidance: revenues now expected between $11.95 billion and $12.05 billion, reported diluted EPS between $9.97 and $10.17, and adjusted diluted EPS between $11.05 and $11.25. The outlook reflects continued demand for diagnostic insights, growth across physician, hospital, and consumer channels, and ongoing productivity improvements from the Invigorate program.